Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects

NCT03092375 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

177

Enrollment

OTHER

Sponsor class

Conditions

Hepatitis C
HCV

Interventions

DRUG: Glecaprevir/Pibrentasvir (G/P) 300mg/120mg
DRUG: Ribavirin 200Mg Tablet

Sponsor

University of Florida

Collaborators

[object Object]
[object Object]